Small modular reactors (SMRs) offer simple, standardized, and safe modular designs for new nuclear reactor construction. They are factory built, requiring smaller initial capital investment and facilitating shorter co...Small modular reactors (SMRs) offer simple, standardized, and safe modular designs for new nuclear reactor construction. They are factory built, requiring smaller initial capital investment and facilitating shorter construction times. SMRs also promise competitive economy when compared with the current reactor fleet. Construction cost of a majority of the projects, which are mostly in their design stages, is not publicly available, but variable costs can be determined from fuel enrichment, average burn-up, and plant thermal efficiency, which are public parameters for many near-term SMR projects. The fuel cost of electricity generation for selected SMRs and large reactors is simulated, including calculation of optimal tails assay in the uranium enrichment process. The results are compared between one another and with current generation large reactor designs providing a rough comparison of the long-term economics of a new nuclear reactor project. SMRs are predicted to have higher fuel costs than large reactors. Particularly, integral pressurized water reactors (iPWRs) are shown to have from 15% to 70% higher fuel costs than large light water reactors using 2014 nuclear fuels market data. Fuel cost sensitivities to reactor design parameters are presented.展开更多
The technological development status of new generation low cost small-lift launch vehicles applied to small satellite launch is investigated in this paper. The development trends are summarized, including low cost and...The technological development status of new generation low cost small-lift launch vehicles applied to small satellite launch is investigated in this paper. The development trends are summarized, including low cost and rapid response capability, utilization of mature rocket and missile technology, the development of mobile launch technology adopting air-based platforms and use of innovative technology. Moreover, the external power and internal demand of the small-lift launch vehicle are analyzed and the market prospect is forecasted. Finally, proposals for the development of small-lift launch vehicles are put forward, including exploration of the potential of existing rocket and missile technology, development of multi-platform mobile launch technology and further application of innovative technology and ideas.展开更多
Objective: To evaluate the cost-effectiveness of atezolizumab plus pemetrexed and platinum-based (APP) in the first-line treatment of non-squamous non- small cell lung cancer (NSCLC). Methods: A partitioned survival m...Objective: To evaluate the cost-effectiveness of atezolizumab plus pemetrexed and platinum-based (APP) in the first-line treatment of non-squamous non- small cell lung cancer (NSCLC). Methods: A partitioned survival model (PSM) was constructed based on the IMpower132 clinical trial. Total cost, quality- adjusted life years (QALY), and incremental cost-effectiveness ratio (ICER) were the main outputs of the model. Deterministic sensitivity analysis and probabilistic sensitivity analysis were adopted to test the uncertainty of the parameters. Results: The results of the base-case analysis illustrated that compared with PP, the incremental cost of APP was CNY 591040.94, the incremental utility was 0.46 QALY, and the ICER was CNY 1291414.83/QALY. Deterministic sensitivity analysis results illustrated that atezolizumab and other parameters have a greater impact on ICER. Probabilistic sensitivity analysis results show that no matter how each parameter changes, under the willingness to pay threshold of 3-times Chinese per capita GDP, the probability of APP has cost-effectiveness is 0. Conclusion: From the perspective of the Chinese health system, APP is not cost-effective for first-line treatment of non-squamous non-small cell lung cancer without sensitizing EGFR or ALK genetic alterations.展开更多
目的评价晚期非小细胞肺癌二线治疗药物帕博利珠单抗、纳武利尤单抗的经济性。方法基于医疗卫生角度,构建动态Markov模型,模拟至99%患者死亡时,产生的医疗成本和质量调整生命年(Qualityadjusted life years,QALYs)。临床参数来自临床试...目的评价晚期非小细胞肺癌二线治疗药物帕博利珠单抗、纳武利尤单抗的经济性。方法基于医疗卫生角度,构建动态Markov模型,模拟至99%患者死亡时,产生的医疗成本和质量调整生命年(Qualityadjusted life years,QALYs)。临床参数来自临床试验和间接比较。成本数据和效用值取自相关网站和已发表的文献。敏感性分析用于评估模型参数的不确定性。结果基础分析结果显示,纳武利尤单抗方案的治疗成本为278634元,获得的QALYs为0.88,帕博利珠单抗方案的治疗成本为232596元,QALYs为0.86,两者的增量成本-效果比(Incremental cost effectiveness ratio,ICER)为2301900元/QALY,均远高于支付阈值(257094元)。单因素敏感性分析显示,药品价格、无进展生存期对ICER的影响较大。结论在当前支付阈值下,纳武利尤单抗较帕博利珠单抗无经济性优势,两者的成本和QALYs值差异不大,药品价格变动极有可能逆转经济性结论。展开更多
文摘Small modular reactors (SMRs) offer simple, standardized, and safe modular designs for new nuclear reactor construction. They are factory built, requiring smaller initial capital investment and facilitating shorter construction times. SMRs also promise competitive economy when compared with the current reactor fleet. Construction cost of a majority of the projects, which are mostly in their design stages, is not publicly available, but variable costs can be determined from fuel enrichment, average burn-up, and plant thermal efficiency, which are public parameters for many near-term SMR projects. The fuel cost of electricity generation for selected SMRs and large reactors is simulated, including calculation of optimal tails assay in the uranium enrichment process. The results are compared between one another and with current generation large reactor designs providing a rough comparison of the long-term economics of a new nuclear reactor project. SMRs are predicted to have higher fuel costs than large reactors. Particularly, integral pressurized water reactors (iPWRs) are shown to have from 15% to 70% higher fuel costs than large light water reactors using 2014 nuclear fuels market data. Fuel cost sensitivities to reactor design parameters are presented.
文摘The technological development status of new generation low cost small-lift launch vehicles applied to small satellite launch is investigated in this paper. The development trends are summarized, including low cost and rapid response capability, utilization of mature rocket and missile technology, the development of mobile launch technology adopting air-based platforms and use of innovative technology. Moreover, the external power and internal demand of the small-lift launch vehicle are analyzed and the market prospect is forecasted. Finally, proposals for the development of small-lift launch vehicles are put forward, including exploration of the potential of existing rocket and missile technology, development of multi-platform mobile launch technology and further application of innovative technology and ideas.
文摘Objective: To evaluate the cost-effectiveness of atezolizumab plus pemetrexed and platinum-based (APP) in the first-line treatment of non-squamous non- small cell lung cancer (NSCLC). Methods: A partitioned survival model (PSM) was constructed based on the IMpower132 clinical trial. Total cost, quality- adjusted life years (QALY), and incremental cost-effectiveness ratio (ICER) were the main outputs of the model. Deterministic sensitivity analysis and probabilistic sensitivity analysis were adopted to test the uncertainty of the parameters. Results: The results of the base-case analysis illustrated that compared with PP, the incremental cost of APP was CNY 591040.94, the incremental utility was 0.46 QALY, and the ICER was CNY 1291414.83/QALY. Deterministic sensitivity analysis results illustrated that atezolizumab and other parameters have a greater impact on ICER. Probabilistic sensitivity analysis results show that no matter how each parameter changes, under the willingness to pay threshold of 3-times Chinese per capita GDP, the probability of APP has cost-effectiveness is 0. Conclusion: From the perspective of the Chinese health system, APP is not cost-effective for first-line treatment of non-squamous non-small cell lung cancer without sensitizing EGFR or ALK genetic alterations.
